Interestingly, anti-ANGPT2 treatment improved vascular integrity and decreased AM discrepancy, especially VCAM-1 and L-selectin, which released sequestered T cells from the periphery into the central tumor areas and reversed the immune-excluded phenotype [142]. Here, ANGPT2 is linked to neoplasm.